CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease

Teh, Yoong Mond; Lim, Soo Kun; Jusoh, Norhana; Osman, Kahar; Mualif, Siti Aisyah

doi:10.1155/2021/6671552

Cited by 9 publications

(4 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD80 was observed primarily expressed on the surface of podocytes, based on the observation, since FSGS caused severe damage to the podocyte. Thus, the expression of CD80 was declined, which leads to presence of CD80 in urine [19].…”

Section: Resultsmentioning

confidence: 99%

Urinary CD80 and Serum Soluble Urokinase Plasminogen Activator Receptor (SuPAR) as Novel Diagnostic Biomarkers in Pediatric Patients with Nephrotic Syndrome

Elghoul

Saad

Abdel-Hafez

et al. 2022

JAMMR

View full text Add to dashboard Cite

Background: This study aimed to evaluate urinary CD80 and serum SuPAR in patients with primary nephrotic syndrome as a non-invasive diagnostic biomarker to predict steroid responsiveness in those patients. Methods: This prospective cohort study was carried out on total 60 children and adolescents with idiopathic nephrotic syndrome (INS) at initial presentation and 30 healthy matched controls. Urinary CD80 and serum SuPAR were measured for all subjects. Patients were divided on follow up into two groups: group A: patients proved to be steroid sensitive nephrotic syndrome (n=30), group B: patients proved to be steroid resistant nephrotic syndrome or proved by biopsy to be focal segmental glomerulosclerosis (n=30). Results: Urinary CD80 levels were significantly higher in group A than group B and C (P <0.001). SuPAR was significantly higher in group B than group A and C (P <0.001). Both urinary CD80 and serum SuPAR were positively correlated to 24h urinary protein, protein/ creatinine ratio and serum cholesterol (P = 0.001, 0.003, <0.001, <0.001 and <0.001 respectively). Also both urinary CD80 and SuPAR were negatively correlated to albumin (P <0.001 and <0.001 respectively). By ROC curve, urinary CD80 can predict steroid sensitivity with 80% sensitivity, 96.67% specificity and accuracy 95% and serum SuPAR can predict steroid resistance with 76.67% sensitivity, 88.33% specificity and accuracy 86%. Conclusions: Urinary CD80 and serum SuPAR can be useful in predicting renal pathology or steroid responsiveness in patients with idiopathic nephrotic syndrome especially if renal biopsy is contraindicated.

show abstract

Section: Resultsmentioning

confidence: 99%

Urinary CD80 and Serum Soluble Urokinase Plasminogen Activator Receptor (SuPAR) as Novel Diagnostic Biomarkers in Pediatric Patients with Nephrotic Syndrome

Elghoul

Saad

Abdel-Hafez

et al. 2022

JAMMR

View full text Add to dashboard Cite

show abstract

“…External factors like viral infections and Treg function can impact the expression of B7-1 (CD80) on podocytes, potentially causing podocyte cytoskeletal disarray and severe proteinuria ( 193 ). CTLA-4, a critical co-factor expressed on podocytes and Tregs, binds to B7-1 (CD80), inhibits T cell activation, and reinstates SS1 integrin activation, thereby alleviating podocyte injury and proteinuria ( 194 ). Contrary to conventional wisdom, recent research challenges the notion of increased B7-1 expression within the podocytes of individuals with proteinuria.…”

Section: Therapeutic Strategies Targeting Immunity In Podocyte Injurymentioning

confidence: 99%

Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy

Jiang,

Shen,

Zhuang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The glomerular filtration barrier, comprising the inner layer of capillary fenestrated endothelial cells, outermost podocytes, and the glomerular basement membrane between them, plays a pivotal role in kidney function. Podocytes, terminally differentiated epithelial cells, are challenging to regenerate once injured. They are essential for maintaining the integrity of the glomerular filtration barrier. Damage to podocytes, resulting from intrinsic or extrinsic factors, leads to proteinuria in the early stages and eventually progresses to chronic kidney disease (CKD). Immune-mediated podocyte injury is a primary pathogenic mechanism in proteinuric glomerular diseases, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and lupus nephritis with podocyte involvement. An extensive body of evidence indicates that podocytes not only contribute significantly to the maintenance of the glomerular filtration barrier and serve as targets of immune responses but also exhibit immune cell-like characteristics, participating in both innate and adaptive immunity. They play a pivotal role in mediating glomerular injury and represent potential therapeutic targets for CKD. This review aims to systematically elucidate the mechanisms of podocyte immune injury in various podocyte lesions and provide an overview of recent advances in podocyte immunotherapy. It offers valuable insights for a deeper understanding of the role of podocytes in proteinuric glomerular diseases, and the identification of new therapeutic targets, and has significant implications for the future clinical diagnosis and treatment of podocyte-related disorders.

show abstract

“…These findings imply limitations in the oral MTX absorption process through active transport. Moreover, potential partial degradation of oral MTX by the gut microbiome may contribute to differences in MTX availability compared to parenteral administration (Teh et al, 2021). Subcutaneous MTX effectively overcomes these limitations, ensuring enhanced and reliable bioavailability compared to oral MTX.…”

Section: Mechanism Of Elisa To Detect Anti-il-2 Antibodiesmentioning

confidence: 99%

Enhancing Rheumatoid Arthritis Treatment by Subcutaneous Methotrexate Injections and Anti-IL-2 Antibody Synthesis

2024

IJAB

View full text Add to dashboard Cite

Article HistoryRheumatoid arthritis (RA), an incapacitating autoimmune disorder marked by joint inflammation, cartilage degradation, and bone erosion, often results in disability. Diagnosis relies on detecting Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), offering insights into disease progression before symptoms emerge. While Methotrexate (MTX) is a standard RA treatment, concerns over insufficient responses and gastrointestinal side effects prompt exploration of subcutaneous MTX injections. This method, established in the USA and Europe and recently approved in Japan, presents a potentially safer and more effective alternative. Additionally, research indicates that elevated Interleukin-2 (IL-2) levels correlate with reduced regulatory T-cell (Treg) levels, exacerbating RA progression. Mouse models demonstrate promise in slowing RA through IL-2 antibody-mediated inhibition, a concept validated in clinical studies involving RA patients. The investigation extends to the potential use of subcutaneous MTX injections as a preferable treatment modality in Pakistan, suggesting a comprehensive approach to managing RA.

show abstract

CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease

Cited by 9 publications

References 146 publications

Urinary CD80 and Serum Soluble Urokinase Plasminogen Activator Receptor (SuPAR) as Novel Diagnostic Biomarkers in Pediatric Patients with Nephrotic Syndrome

Urinary CD80 and Serum Soluble Urokinase Plasminogen Activator Receptor (SuPAR) as Novel Diagnostic Biomarkers in Pediatric Patients with Nephrotic Syndrome

Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy

Enhancing Rheumatoid Arthritis Treatment by Subcutaneous Methotrexate Injections and Anti-IL-2 Antibody Synthesis

Contact Info

Product

Resources

About